You are here

Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
5-4-12, Kitashinagawa, Shinagawa-ku, 141-0001 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease, Healthy
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT00441987
Pfizer
Completed
Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Healthy Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
Chronic Disease, Pain
NCT01179191
All Genders
21+
Years
Multiple Sites
Normal Healthy
NCT02871037
All Genders
18+
Years
New Haven, Connecticut
Gastroesophageal Reflux Disease
NCT02401035
All Genders
1+
Years
Multiple Sites
Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953
A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 Administered Orally to Healthy Japanese Male Subjects and Healthy Elderly Male Japanese Subjects.
The purpose of the protocol is to assess the initial pharmacokinetic (PK) profile of a single oral dose of GSI-953 to healthy male Japanese subjects and healthy elderly male Japanese subjects.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Alzheimer Disease
  • Healthy
Drug: GSI-953
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
96
July 2009
July 2009   (Final data collection date for primary outcome measure)
  • Healthy males aged 20 - 40 and healthy males aged greater than 65.
  • Body mass index range of 17.6 - 26.4 kg/m2 greater than or equal to 45 kg.
  • Non-smokers or smoker of fewer than 10 cigarettes a day.
Sexes Eligible for Study: Male
20 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00441987
3183A1-101
Not Provided
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
June 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now